AbCellera Says ABCL635 Cut Hot Flashes in Phase 2 Trial

What happened

AbCellera Biologics Inc. (Nasdaq: ABCL) said on August 10, 2026 that ABCL635, its experimental non-hormonal treatment for moderate-to-severe vasomotor symptoms due to menopause, met the primary efficacy endpoints in the Phase 2 portion of a Phase 1/2 study, according to the company's investor relations release and coverage by Reuters-owned RTTNews, Yahoo Finance and Stock Titan.

The company said the trial showed statistically significant reductions in both the frequency and severity of moderate-to-severe vasomotor symptoms after a single dose, with results measured at week 4 compared to placebo. Stock Titan reported an 83% reduction in hot flashes. Yahoo Finance described ABCL635 as an investigational non-hormonal treatment.

The company had previously announced, in its own investor relations release, that it would report top-line Phase 2 results for ABCL635 on Monday, August 10, 2026.

Despite the reported positive data, AbCellera shares closed at $10.46, down 5.34% from the prior close of $11.05, according to the price data accompanying this report. RTTNews had reported the stock jumped 33% on the news; the closing price does not reflect that move. The sources do not explain the discrepancy between the reported intraday jump and the lower close.

AbCellera is a clinical-stage antibody discovery company. It built its business around a technology platform for finding antibodies, and has been expanding into developing its own drug candidates rather than only partnering with other companies.

What the trial measured

Vasomotor symptoms are the hot flashes and night sweats associated with menopause. The trial enrolled people with moderate-to-severe symptoms — meaning frequently occurring episodes that interfere with daily life.

A Phase 1/2 study is a combined early-stage trial. Phase 1 typically tests safety and how the body processes a drug in a small number of people; Phase 2 tests whether the drug appears to work in a larger group. Combining them lets a company move quickly from safety to a first look at efficacy.

The primary efficacy endpoint is the specific measurement a trial is designed in advance to answer. Here, that was a reduction in how often and how severely hot flashes occurred, measured four weeks after a single dose compared to placebo. Meeting the primary endpoint means the difference between drug and placebo was statistically significant — unlikely to be due to chance.

The company's release described the results as "best-in-class," and said ABCL635 had a favorable tolerability profile, meaning side effects were manageable. The release did not disclose the size of the trial or the specific numerical reductions in frequency and severity; those details were not available in the sources reviewed.

The company said this was a single-dose result. Most treatments for menopausal symptoms are taken repeatedly; a single-dose effect measured at four weeks is a preliminary signal, not proof of durable benefit.

Analyst reaction

Posts on X claimed analyst price target increases into the $25 to $30 range. Those claims are not supported by any filing or named news outlet reviewed here and are not reported as fact.

No named analyst commentary, target change, or rating action was found in the verifiable sources for this event. Yahoo Finance and Stock Titan reported the results and the stock reaction but did not include specific analyst notes.

What this means

AbCellera does not have a marketed drug. Its revenue has come from partnering with other companies, which pay it to discover antibodies using its platform. Advancing its own candidate, ABCL635, through clinical trials is a different kind of bet: the company bears more of the cost, but keeps more of the potential value if the drug works.

For a company like this, a Phase 2 result is a gate. If the data are positive, the company typically proceeds to a larger Phase 3 trial that is designed to confirm the benefit in more patients and support an application to the U.S. Food and Drug Administration. The company's own release framed the results as supporting further development, but did not state a specific next step or timeline in the sources reviewed.

Large Phase 3 trials are expensive. AbCellera, like many clinical-stage biotechs, holds cash and reports its financial position periodically; its second-quarter 2026 business results were also published on its investor relations site. A positive mid-stage result often prompts a company to discuss funding, partnerships, or a potential licensing deal for the asset.

The market reaction is the other half of the story. A stock can trade on whether data beat expectations rather than whether data are good in absolute terms. The sources do not explain why ABCL635 shares closed lower on the day despite the reported positive top-line results and the reported intraday jump, and this report does not speculate as to the cause.

Note that no SEC filing accompanied this announcement in the sources reviewed. The event was reported through AbCellera's investor relations news release and covered by RTTNews, Yahoo Finance, and Stock Titan. A company of AbCellera's size is not necessarily required to file a Form 8-K for clinical trial results, depending on materiality judgments; the absence of a filing in the sources reviewed is not itself evidence of anything.